# US 2004/0205833 A1 · Human disease modeling using somatic gene transfer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0205833 A1
- Document ID: US20040205833A1
- Status: Published application
- Kind: A1
- Application number: 10/477,167
- Filed: 2004-06-01
- Published: 2004-10-14
- Earliest claimed: 2001-02-09
- Inventors: Ronald Klein; Edwin M Meyer; Nicholas Muzyczka; Michael A King; Craig A Meyers
- Web page: https://patentgrep.com/patent/US20040205833A1

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- C07K 14/47: from mammals
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C12N 15/86: Viral vectors
- G01N 33/5088: {of vertebrates}
- A01K 2207/15: Humanized animals
- A01K 2217/00: Genetically modified animals
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A01K 2267/0312: Animal model for Alzheimer's disease
- A01K 2267/0318: Animal model for neurodegenerative disease, e.g. non- Alzheimer's
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2810/6018: Adenoviridae
- C12N 2830/00: Vector systems having a special element relevant for transcription
- C12N 2830/15: chimeric enhancer/promoter combination
- C12N 2830/60: from viruses
- C12N 2830/90: avian
- C12N 2840/20: translation of more than one cistron
- C12N 2840/203: having an IRES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides a system for modeling neurodegenerative and other diseases through somatic gene transfer. In addition, methods of multiple gene transfer, disease analysis and drug testing are provided for.

## Claims

### Claim 1

A method for producing a non-human animal model of a human disease which comprises transferring at least one aberrant form of at least one gene known to be associated with said disease in humans into appropriate tissue of a living non-human animal under conditions which result in the expression of said at least one aberrant gene, wherein said transferring does not require the modification of the germ-line of said living animal.

### Claim 2 (depends on 1)

The method according to claim 1 wherein said human disease is a neurodegenerative disease.

### Claim 3 (depends on 2)

The method according to claim 2 wherein said human disease is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.

### Claim 4 (depends on 3)

The method according to claim 3 wherein said at least one gene is an aberrant form of tau.

### Claim 5 (depends on 3)

The method according to claim 3 wherein said aberrant form of tau is P301L, associated with “fronto-temporal dementia with Parkinson's linked to chromosome 17 (FTDP-17)”.

### Claim 6 (depends on 3)

The method according to claim 3 wherein said at least one gene is an aberrant form of alpha-synuclein.

### Claim 7 (depends on 6)

The method according to claim 6 wherein said aberrant form of alpha-synuclein is mutant α-synuclein (A30P), associated with Parkinson's Disease.

### Claim 8 (depends on 3)

The method according to claim 3 wherein said at least one gene is a mutant amyloid precursor protein (APP), a mutant presenilin-1 (PS1), or combinations thereof, associated with Alzheimer's Disease.

### Claim 9 (depends on 1)

The method according to claim 1 which comprises identifying a combination of genes relevant to a particular human pathology and somatically transferring combinations of said genes into tissues appropriate to said particular human pathology in a non-human animal model appropriate to said human pathology.

### Claim 10 (depends on 1)

The method according to claim 1 comprising:
(a) controlling the location to which the genes are transferred, that is spatially controlling gene expression of the transferred genes, in the non-human animal model to which said at least one gene is transferred;
(b) controlling the temporal effects of transferred genes at specific times in the development of otherwise normal organisms, or in the development of organisms in which germline modifications have previously been made, by selecting the time at which said transferred genes are introduced into said organism, or by controlling the time of expression of said transferred genes;
(c) evaluating the effects of expression of combinations of multiple transgenes, which in a germline transgenic non-human animal would be difficult if not impossible to achieve due to diseases which might prevent the animal model from maturing to the age-appropriate state for modeling onset of a particular, complex human disease;
(d) increasing the rate for analyzing multiple genes which contribute to complex, multifactorial human diseases by transferring more than a single gene into an appropriate non-human animal model for said disease;
(e) testing pharmaceutical agents for their ability to ameliorate specific diseases induced in said non-human animal model;
(f) studying specific human pathologies induced in said non-human animal model by inducing said pathology in said animal model by transferring said at least one gene into said animal model;
(g) supplementing an existing germline transgenic model with additional somatically provided gene products to modulate the transgenic model;
(h) creating a disease condition in an otherwise healthy animal; and combinations of (a)-(h).

### Claim 11 (depends on 1)

A non-human animal produced by the method of claim 1.

### Claim 12 (depends on 11)

A pharmaceutical identified through testing of pharmaceutical compounds using the non-human animal produced according to claim 11.

### Claim 13

A method for inducing neurofibrillary tangles in the brain of a non-human animal which comprises injecting into the brain of said animal an effective amount of a gene expression construct encoding tau, alpha-synuclein, presenilin-1, amyloid precursor protein, IL6, or a combination thereof.

### Claim 14 (depends on 13)

A non-human animal produced according to the method of claim 13.

### Claim 15

A method for inducing behavioral changes in a non-human animal model which comprises somatic administration of at least one gene directly to the brain of said non-human animal, wherein said at least one gene is associated with a human neurodegenerative disease.

### Claim 16 (depends on 1)

The method according to claim 1 wherein said at least one aberrant form of said at least one gene is transferred by means of an adeno-associated virus.

### Claim 17

A method of identifying a pharmacologically active substance that slows, reduces, reverses or eliminates the adverse effects of a degenerative neurological disease, comprising:
a. transferring at least one aberrant form of at least one gene known to be associated with said disease in humans into appropriate tissue of a living non-human animal under conditions which result in the expression of said at least one aberrant gene, wherein said transferring does not require the modification of the germ-line of said living animal;
b. repeating step “a” for a sufficient number of living non-human animals to evaluate a desired number of pharmacologically active substances at a desired number of concentrations, combinations, administration regimes, and evaluation schedules;
c. exposing a specified number of said sufficient number of living non-human animals of step “b” to a specific pharmacologically active substance at a desired number of concentrations and administration regimes, and optionally repeating this exposing for each of a desired number of additional specific pharmacologically active substance(s); and
d. evaluating said specific pharmacologically active substance(s) of step “c”;
wherein said evaluating provides information that identifies at least one pharmacologically active substance that slows, reduces or eliminates the adverse effects of a degenerative neurological disease.

### Claim 18 (depends on 17)

The method of claim 17, wherein the step “c” exposing begins prior to said transferring of at least one gene of steps “a” and “b”.

### Claim 19 (depends on 17)

The method of claim 17, wherein the step “c” exposing begins prior to and continues after said transferring of at least one gene of steps “a” and “b”.

### Claim 20 (depends on 17)

The method of claim 17, wherein the step “c” exposing begins after said transferring of at least one gene of steps “a” and “b”.

### Claim 21 (depends on 17)

The method of claim 17, wherein the effects of at least one nutrient regime and/or the effects of at least one environmental stressor also are evaluated.

### Claim 22

A method of identifying a nutrient regime that slows, reduces, reverses or eliminates the adverse effects of a degenerative neurological disease, comprising:
a. transferring at least one aberrant form of at least one gene known to be associated with said disease in humans into appropriate tissue of a living non-human animal under conditions which result in the expression of said at least one aberrant gene, wherein said transferring does not require the modification of the germ-line of said living animal;
b. repeating step “a” for a sufficient number of living non-human animals to evaluate a desired number of pharmacologically active substances at a desired number of concentrations, combinations, administration regimes, and evaluation schedules;
c. exposing a specified number of said sufficient number of living non-human animals of step “b” to a specific pharmacologically active substance at a desired number of concentrations and administration regimes, and optionally repeating this exposing for each of a desired number of additional specific pharmacologically active substance(s); and
d. evaluating said specific pharmacologically active substance(s) of step “c”;
wherein said evaluating provides information that identifies at least one pharmacologically active substance that slows, reduces or eliminates the adverse effects of a degenerative neurological disease.

### Claim 23

A method of identifying an environmental inducer that aggravates, induces, or otherwise contributes to the adverse effects of a degenerative neurological disease, comprising:
a. transferring at least one aberrant form of at least one gene known to be associated with said disease in humans into appropriate tissue of a living non-human animal under conditions which result in the expression of said at least one aberrant gene, wherein said transferring does not require the modification of the germ-line of said living animal;
b. repeating step “a” for a sufficient number of living non-human animals to evaluate a desired number of pharmacologically active substances at a desired number of concentrations, combinations, administration regimes, and evaluation schedules;
c. exposing a specified number of said sufficient number of living non-human animals of step “b” to a specific environmental inducer at a desired number of concentrations and administration regimes, and optionally repeating this exposing for each of a desired number of additional specific environmental inducer(s); and
d. evaluating said specific environmental inducer(s) of step “c”;
wherein said evaluating provides information that identifies at least one environmental inducer that aggravates, induces, or otherwise contributes to the adverse effects of a degenerative neurological disease.
